The project for objective measures using computational psychiatry technology (PROMPT): Rationale, design, and
Taishiro Kishimoto1, Akihiro Takamiya1, Kuo-Ching Liang1
1Department of Neuropsychiatry, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan.
This study aims to develop objective digital biomarkers for assessing depressive and neurocognitive disorders. Computational psychiatry and machine learning will analyze speech, motion, and activity data to improve diagnosis and treatment monitoring.
Area of Science:
- Computational psychiatry
- Digital biomarkers
- Machine learning in mental health
Background:
- Depressive and neurocognitive disorders are leading causes of global disability.
- Lack of objective biomarkers hinders treatment assessment and drug development.
- New technologies enable quantification of clinically relevant behavioral features.
Purpose of the Study:
- To develop objective, noninvasive, and easy-to-use biomarkers for assessing depressive and neurocognitive disorders.
- To guide clinical decision-making and reduce clinical trial failure rates.
- To leverage computational psychiatry and machine learning for objective mental health assessment.
Main Methods:
- Recruitment of patients with major depressive disorder, bipolar disorder, neurocognitive disorders, and healthy controls.
- Conducting 10-minute conversational interviews recorded via RGB/infrared cameras and microphones.
- Utilizing wearable devices and advanced software for data processing and machine learning analysis.
Main Results:
- Machine learning models are employed to predict symptom presence, severity, and changes over time.
- Analysis of multimodal data including video, audio, and wearable sensor information.
- Focus on extracting features that reflect disorder severity across diverse patient samples.
Conclusions:
- The Project for Objective Measures Using Computational Psychiatry Technology (PROMPT) aims to create practical biomarkers.
- Objective measures can improve clinical practice and streamline psychiatric drug development.
- Addressing sample variability is crucial for robust biomarker extraction.
More Related Videos
13:09Using Brain Activation nir-HEG/Q-EEG and Execution Measures CPTs in a ADHD Assessment Protocol
Published on: April 1, 2018
16:23Automated, Quantitative Cognitive/Behavioral Screening of Mice: For Genetics, Pharmacology, Animal Cognition and Undergraduate Instruction
Published on: February 26, 2014
